For patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node-positive, high-risk ...

The investigational PAM inhibitor extends progression-free survival from 5 to 7 months in patients with advanced, PIK3CA wild ...

The monarchE trial's primary overall survival (OS) analysis presented at ESMO 2025 confirms that 2 years of ...

I was 19 when I dragged myself — half-hearted and unimpressed — to the compulsory Breast Cancer Awareness seminar at Fatima Jinnah Women University in Rawalpindi. I was just a young undergraduate ...

Sacituzumab govitecan significantly improved survival outcomes for previously untreated, PD-L1-negative metastatic ...

Oct. 14, days before the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, Merck & Co. | Merck has just ...

At ESMO 2025, Eli Lilly’s Verzenio and Novartis’ Kisqali both demonstrated durable efficacy in hormone receptor-positive, ...

A newly developed antibody which restricts the growth of treatment-resistant breast cancers offers new hope for patients.

T-DXd plus pertuzumab significantly improved PFS in HER2-positive advanced breast cancer, outperforming the THP regimen across various subgroups. The combination therapy showed higher objective ...

Zurich, 23 October 2025. Elixion Biotech emerges from stealth, announcing the in-silico validation of five targets via its ...

Verzenio plus endocrine therapy reduced death risk by 15.8% in high-risk early breast cancer patients compared to endocrine ...

Puma Biotechnology will issue financials and host a conference call on Nov. 6, 2025 to discuss its results for the third ...